Compare BORR & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BORR | NUVB |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Bermuda | United States |
| Employees | N/A | 298 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2017 | N/A |
| Metric | BORR | NUVB |
|---|---|---|
| Price | $5.02 | $4.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $6.25 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 7.9M | 4.4M |
| Earning Date | 05-20-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.80 | $203.82 |
| Revenue Next Year | $21.67 | $58.18 |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $1.57 |
| 52 Week High | $6.66 | $9.75 |
| Indicator | BORR | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 32.70 | 51.76 |
| Support Level | $4.65 | $4.07 |
| Resistance Level | $6.26 | $5.23 |
| Average True Range (ATR) | 0.33 | 0.28 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 3.54 | 60.75 |
Borr Drilling Ltd is an offshore shallow-water drilling contractor providing services to the oil and gas industry. Its operations focus on the ownership, contracting, and operation of jack-up rigs in shallow-water areas, including the provision of related equipment and work crews to conduct oil and gas drilling and workover operations for exploration and production (E&P) customers. The company contracts its rigs on a dayrate basis to drill wells for integrated oil companies, state-owned national oil companies, and independent oil and gas companies. It operates in one reportable segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.